Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in solar cells and other energy conversion devices
US-2024115878-A1 · Apr 11, 2024 · US
Compositions and methods for treatment of cardiovascular disorders
US9737569B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9737569-B2 |
| Application number | US-201514644476-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2015 |
| Priority date | Jan 18, 2006 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition for treating damaged cardiovascular tissue, comprising: an extracellular matrix (ECM) composition consisting of acellular ECM from basement membrane of amniotic membrane and a combination of exogenously added growth factors selected from the group consisting of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) or transforming growth factor beta (TGF-β), wherein a growth factor augmented ECM composition is formed, whereby, when said growth factor augmented ECM composition is delivered to infarcted cardiovascular tissue, said growth factor augmented ECM composition induces angiogenesis, bioremodeling of said infarcted cardiovascular tissue and regeneration of new cardiovascular tissue structures with site-specific structural and functional properties. 2. A method for treating a cardiovascular disorder, comprising the steps of: providing the extracellular matrix (ECM) composition according to claim 1 ; and administering said ECM composition to infarcted cardiovascular tissue associated with said cardiovascular disorder.
Assignees
Inventors
Classifications
- A61K35/12Primary
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title
Animal cells · CPC title
Growth factors · CPC title
of enzymes · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9737569B2 cover?
- ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.
- Who is the assignee on this patent?
- Cormatrix Cardiovascular Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K35/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).